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ARTICLE
Neutralizing antibodies against Mayaro virus require
Fc effector functions for protective activity
James T. Earnest1, Katherine Basore2, Vicky Roy3, Adam L. Bailey2, David Wang2,4, Galit Alter3, Daved H. Fremont2,4,5, and Michael S. Diamond1,2,4,6
Despite causing outbreaks of fever and arthritis in multiple countries, no countermeasures exist against Mayaro virus (MAYV),
an emerging mosquito-transmitted alphavirus. We generated 18 neutralizing mAbs against MAYV, 11 of which had “elite”
activity that inhibited infection with EC50 values of <10 ng/ml. Antibodies with the greatest inhibitory capacity in cell culture
mapped to epitopes near the fusion peptide of E1 and in domain B of the E2 glycoproteins. Unexpectedly, many of the elite
neutralizing mAbs failed to prevent MAYV infection and disease in vivo. Instead, the most protective mAbs bound viral antigen
on the cell surface with high avidity and promoted specific Fc effector functions, including phagocytosis by neutrophils and
monocytes. In subclass switching studies, murine IgG2a and humanized IgG1 mAb variants controlled infection better than
murine IgG1 and humanized IgG1-N297Q variants. An optimally protective antibody response to MAYV and possibly other
alphaviruses may require tandem virus neutralization by the Fab moiety and effector functions of the Fc region.
Introduction
Mayaro virus (MAYV) is a mosquito-transmitted arthritogenic
alphavirus in the Togaviridae family of positive-stranded RNA
viruses. MAYV was first described in 1954 in Trinidad (Causey
and Maroja, 1957) and now circulates in the Caribbean Islands
and South America (Causey and Maroja, 1957; Pinheiro et al.,
1981; Azevedo et al., 2009). MAYV infection causes an acute
febrile illness that initially is indistinguishable from other ar-
boviruses, including chikungunya virus (CHIKV), dengue, and
Zika viruses. A study of a MAYV outbreak in Brazil showed a
high incidence of severe arthralgia (55%) and myalgia (49%),
which can persist for months to years (Mourão et al., 2012).
There are no vaccines or therapeutics available for the preven-
tion or treatment of MAYV infection.
MAYV is transmitted principally by Haemagogus species
mosquitoes among primates in a sylvatic cycle, with intermittent
spillover to human populations. However, there is concern that
even single mutations in MAYV could lead to changes in vector
competence, as occurred with CHIKV in La Reunion Island in
2006. In that case, CHIKV acquired the ability to infect Aedes
albopictus mosquitoes more efficiently, which resulted in an ur-
ban transmission cycle (Tsetsarkin et al., 2007). Aedes mosqui-
toes can be infected by MAYV, although the levels of virus
in blood required for transmission from viremic humans are
considered insufficient for epidemic transmission (Brustolin
et al., 2018). In comparison, four different Anopheles mosqui-
toes can transmit MAYV (Brustolin et al., 2018). As these species
are native to distinct geographic regions (Africa, Asia, and North
America), they could facilitate the global spread of MAYV.
The MAYV genome encodes for four nonstructural proteins
(nsp1–nsp4) and five structural proteins (capsid, E3, E2, 6K, and
E1). Alphavirus envelope glycoproteins associate in the endo-
plasmic reticulum and form a heterotrimer comprised of the E3,
E2, and E1 proteins (Carleton et al., 1997). E3 is cleaved by furin-
like proteases during the maturation process in the trans-Golgi
network (Heidner et al., 1996). The mature alphavirus virion
is ∼700 A˚ in diameter and contains a lipid bilayer with 240
E2–E1 heterodimers assembled into 80 trimeric spikes with T = 4
icosahedral symmetry (Paredes et al., 1993; Cheng et al., 1995;
Kostyuchenko et al., 2011) and a nucleocapsid containing a single
copy of genomic RNA. As the E1 and E2 glycoproteins are dis-
played prominently on the viral spike, they are targets of anti-
body responses.
Although mAbs that specifically bind the envelope glyco-
proteins of MAYV have not yet been described, others generated
in the context of immunization with CHIKV antigens have shown
cross-reactivity and cross-neutralizing activity with MAYV
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(Fox et al., 2015). In the context of human polyclonal antibody
responses to MAYV, antibody responses to E1 and E2 proteins
have been detected, with greater cross-reactivity among those
recognizing E2 (Smith et al., 2018). However, these studies have
not fully elucidated the epitopes and mechanisms by which an-
tibodies against MAYV are protective in vivo.
Here, we produced and characterized a panel of 18 neutral-
izing anti-MAYV mAbs after immunizing mice with infectious
virus and recombinant MAYV E2 protein. 11 of these anti-MAYV
mAbs showed exceptional potency in cell culture with half-
maximal effective inhibitory concentration (EC50) of <10 ng/ml.
All but two of these antibodies were capable of neutralizing 11
different strains of MAYV that we tested. Several anti-MAYV
mAbs cross-neutralized related arthritogenic alphaviruses,
including CHIKV, Una virus (UNAV), Ross River virus (RRV),
and O’nyong’nyong virus (ONNV), whereas others were
MAYV specific. Our neutralizing anti-MAYV mAbs generally
blocked infection at a postattachment step, preventing fusion
of virus–host membranes and impairing viral egress. Epitope
mapping analyses revealed that 16 of the mAbs bound epitopes
in the B domain of the E2 glycoprotein, with two others rec-
ognizing a site in the E1 glycoprotein proximal to the fusion
loop (FL) peptide. A subset of the strongly neutralizing mAbs
protected mice from lethal MAYV challenge and virus-
induced joint swelling and dissemination. Despite the potent
neutralizing activity observed in cell culture, protection re-
quired fragment crystallizable (Fc) effector functions, since
isotype-switched or aglycosyl variants with less or no capacity
to interact with the complement component C1q or activating
Fc-γ receptors (FcγR) lost protective activity in vivo. Our re-
sults in mice suggest that strategies to induce highly protec-
tive antibodies against MAYV may require designs that
optimize both neutralizing activity and Fc effector functions.
Results
Generation of anti-MAYV mAbs
We inoculated BALB/c mice with MAYV strain CH and boosted
twice with recombinant, bacterially produced MAYV E2 ecto-
domain (amino acids 1–340) in Freund’s incomplete adjuvant
and then one additional time with MAYV-CH (see Materials and
methods), as we did to generate anti-CHIKV mAbs (Pal et al.,
2013). Serum had neutralization titers in cell culture of >1/
10,000 against MAYV-CH. After a final intravenous boost with
MAYV-CH, we performed splenocyte-myeloma fusions from
four mice. Subsequently, 151 anti-MAYV mAbs were subcloned
and isolated. Supernatant from 18 of these hybridomas con-
tained antibodies that reduced MAYV infection by >80% in Vero
cells. These mAbs were isotyped (Table 1) and purified by pro-
tein A affinity chromatography.
The purified mAbs were evaluated by focus reduction neu-
tralization test (FRNT) for inhibition of infection of the immu-
nizing MAYV-CH strain as well as 10 other MAYV strains
(described in Powers et al., 2006) encompassing the predominant
D and L genotypes (Figs. 1 A and S1), isolated between 1955 and
2002 (Table S1). These strains exhibit a high degree of amino acid
sequence identity in the E1 (94–100%; Fig. S2) and E2 (96–100%;
Fig. S3) glycoproteins. Only a single strain in the N genotype
exists (Auguste et al., 2015), and it was not available to us for
evaluation. 11 of the 18 mAbs potently inhibited infection of
MAYV-CH (Table 1 and Fig. 1 B) and the majority neutralized a
range of MAYV strains from the D and L genotypes. Only two
mAbs showed a complete loss of neutralization activity against
one or more MAYV strains (MAY-133: Uruma strain; and MAY-
140: FSB0311, OBS6443, and BeH473130 strains; Table 1). For
others, a >10-fold decrease in inhibitory activity against different
MAYV strains compared withMAYV-CHwas observed with 13 of
the 18 mAbs. Only mAbsMAY-116, MAY-122, MAY-131, MAY-146,
and MAY-151 maintained potency (<10-fold reduction in EC50
values compared with CH strain) across all tested MAYV strains
(Table 1). We also performed neutralization assays with MAYV-
BeH407 in C2C12 myoblast and embryonic fibroblast cells and
observed similar inhibitory activity (Fig. S1). Because our vacci-
nation strategy included boosting with recombinant E2 protein,
we measured antibody affinity to E2 protein using biolayer in-
terferometry (BLI; Tables 1 and S2). The KD, equilibrium (equilib-
rium dissociation constant) rate for the mAbs ranged from 3 to
243 nM, with eight demonstrating high-affinity monovalent
binding of <20 nM. MAY-115 and MAY-131 had no detectable
binding to E2, suggesting they recognized a different structural
protein (i.e., E1) or a quaternary epitope on E2 displayed exclu-
sively on the virion. MAY-122, likely the most consistently potent
neutralizing antibody across all MAYV strains, had the second
highest affinity, with a KD of 4 nM.
Breadth of alphavirus neutralization of anti-MAYV mAbs
To assess whether the anti-MAYV mAbs inhibited related ar-
thritogenic alphaviruses, we first assessed cross-reactive bind-
ing by flow cytometry to permeabilized cells infected with
UNAV, CHIKV, RRV, and ONNV (Fig. 2 A). Of the 18mAbs tested,
16, 10, 3, and 1 cross-reacted with UNAV, CHIKV, RRV, and
ONNV, respectively (Table 2). We next tested the cross-reactive
mAbs for their ability to cross-neutralize infection. All 16 mAbs
that bound UNAV-infected cells neutralized this virus (Fig. 2 B).
Similar results were observed with RRV and ONNV, with all
mAbs that bound infected cells neutralizing the respective virus
(Fig. 2, D and E). For CHIKV, only 3 of the 10 mAbs that bound
infected cells substantially inhibited CHIKV infection in cells
(Fig. 2 C). Although MAY-117 and MAY-120 neutralized UNAV,
CHIKV, and RRV, none of our anti-MAYV mAbs inhibited in-
fection of all of the arthritogenic alphaviruses that we tested
(Fig. 2).
Mechanism of neutralization by anti-MAYV mAbs
Antibodies against alphaviruses can inhibit attachment, inter-
nalization, fusion, or budding and egress (Fox et al., 2015; Jin
et al., 2015, 2018; Kim et al., 2019). To assess how the panel of
neutralizing anti-MAYV mAbs blocked infection, we first per-
formed attachment inhibition assays in which mAbs and virus
were premixed at 4°C before addition to Vero cells. After ex-
tensive washing, viral RNA adsorbed to cells was measured by
quantitative RT-PCR (qRT-PCR). As a positive control, pre-
treatment ofMAYVwith soluble heparin, a molecule that closely
mimics the attachment factor heparan sulfate (Klimstra et al.,
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1998), blocked MAYV attachment dose dependently (Fig. 3 A).
Only MAY-118 and MAY-122 modestly inhibited virus binding,
with 28% and 24% reductions, respectively (Fig. 3 B).
We next determined whether our panel of neutralizing mAbs
inhibited at a postattachment step. Neutralization assays were
performed by adsorbing virus to cells at 4°C before addingmAbs.
All anti-MAYV mAbs tested potently inhibited infection when
added before virus attachment to cells (Fig. 3 C), as expected.
The mAbs also had similar EC50 values when added after virus
attachment (Fig. 3 D). As these results suggested that mAb in-
hibition occurred after virus binding to cells, we assessed their
capacity to block viral fusion. We performed fusion-from-
without (FFWO) assays (Edwards and Brown, 1986). MAYV was
bound to target cells at 4°C before addition of mAbs. After re-
moving unbound antibody and virus, membrane fusion was
induced by a pulse exposure to acidic medium (pH 5.5). After pH
Figure 1. Anti-MAYV mAbs neutralize strains from both D and L genotypes. (A) Viral strains were subjected to next-generation sequencing. A phylo-
genetic tree was generated using a Jukes–Cantor genetic distance model by aligning structural gene nucleotide sequences for each MAYV strain. (B) Serial
dilutions of mAbs were incubated with 102 FFU of the indicated MAYV strain, representing either genotypes D (top) or L (bottom), before inoculation of Vero
cells. Cells were overlaid with methylcellulose and incubated for 18 h. Viral foci were stained, counted, and plotted relative to a no-antibody control. Data are
representative of two experiments performed in triplicate. Error bars represent SD within one experiment.
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neutralization, cells were incubated in medium supplemented
with 20 mM NH4Cl to prevent MAYV fusion via canonical en-
dosomal pathways. After 18 h, cells were stained for intracellular
MAYV E2 proteins. As expected, neutral pH medium did not
result in expression of MAYV E2 antigen, as plasma membrane
fusion did not occur (Fig. 3 E). However, a short exposure of cell
surface–adsorbed virus to acidic pH resulted in viral fusion and
MAYV E2 antigen expression, and 16 of the 18 mAbs blocked
this, whereas the isotype control mAbs did not (Fig. 3 F).
We evaluated whether anti-MAYV neutralizing mAbs could
block viral egress, presumably by binding to structural glyco-
proteins on the plasma membrane and inhibiting assembly or
budding (Fox et al., 2015; Jin et al., 2015, 2018). Vero cells were
transfected with RNA isolated from MAYV-infected cells. The
cells were treated with anti-MAYV mAbs, and the amount of
RNase A–resistant, encapsidated viral RNA released into the
supernatant was monitored. At 1 h, the levels of viral RNA in the
supernatant were at the limit of detection (Fig. 3 G), indicating
an absence of de novo synthesized and secreted virions. By 6 h,
however, a 10,000-fold increase in encapsidated viral RNA was
observed in the supernatant of the isotype control mAb–treated
cells (Fig. 3 G). All of the mAbs tested, except MAY-125 and
MAY-133, diminished the amount of viral RNA in the superna-
tant at doses of 10 µg/ml, suggesting a capacity to block MAYV
egress. The potency of this inhibition was variable among the
mAbs tested, as 11 of the 18 mAbs lost the ability to inhibit egress
when a concentration of 0.1 µg/ml was used (Fig. 3 H).
Epitope mapping of anti-MAYV mAbs
Our BLI data indicated that the majority of mAbs bound to the E2
protein (Tables 1 and S2). We next tested whether these mAbs
recognized the B domain of E2, a target of neutralizing anti-
bodies against other alphaviruses (Fox et al., 2015; Weger-
Lucarelli et al., 2015). Of the 18 mAbs tested, 16 bound to the
E2 B domain by ELISA (Fig. S4, A and B). We used two methods
to map these B domain–specific mAbs at the amino acid level: (1)
mAb binding to recombinant E2 proteins produced with sub-
stitutions in predicted solvent-exposed amino acids in the B
domain (based on the CHIKV pE2-E1 structure; PDB: 3N42) from
nonconserved residues present in other alphaviruses (Fig. 4,
A–C; and Fig. S4 C); and (2) alanine scanning mutagenesis of
the E2 B domain in the context of the full-length structural
polyprotein (C-E3-E2-6K-E1). 293T cells were transfected with
plasmids containing a single alanine substitution in residues
173–231 of the E2 protein, except at position 227, when the ala-
nine was substituted to serine (Fig. 4, D–F; and Fig. S4 D). The 16
mAbs mapped to three regions within the E2 B domain: residues
181–190 (Fig. 4, A, D, and G; blue), 205–211 (Fig. 4, B, E, and G;
red), and 214–218 (Fig. 4, C, F, and G; green). A majority of the
mAbs bound to one of two loops (amino acids 179–186 and
Figure 2. Cross-reactivity and cross-
neutralization of related arthritogenic alphavi-
ruses. (A) Dendrogram showing the phylogenetic
relationship of the structural genes of related al-
phaviruses used for cross-neutralization testing.
(B–E) Neutralization assays were performed with
anti-MAYV mAbs that bound to cells infected by
UNAV (B), CHIKV (C), RRV (D), or ONNV (E). Serial
dilutions of the indicated mAbs were incubated with
102 FFU of the indicated alphavirus before inocula-
tion of Vero cells as described in Fig. 1. Data are
representative of two experiments performed in
triplicate. Error bars represent SD within one
experiment.
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212–218) that are predicted to protrude from the E2–E1 hetero-
dimer.Wemade additional charge substitutions in these loops to
determine if secondary structure was important for mAb bind-
ing. Whereas mutations to residues T212 and T213 impacted
protein expression and could not be evaluated, the remaining
mutations in these loops led to decreased binding of the mAbs
mapping to these regions (Fig. 4, D and F; and Fig. S4 D). In
several instances, charge mutations led to loss of mAb binding
when alanine mutations did not. Likely, the mAbs do not rec-
ognize these residues directly but rather the chemical properties
of the amino acid side chains maintain the architecture of the
loop and preserve the epitopes.
Two mAbs, MAY-115 and MAY-131, did not bind to recombi-
nant E2 proteins (Fig. S4, A and B). To determine their epitopes,
we selected for neutralization escape viruses. MAYV CH was
propagated in Vero cells in the presence of MAY-115 or MAY-131
for at least six passages until neutralization activity was lost. The
structural genes of the escape mutants were sequenced. Muta-
tions in the E1 gene were identified for both MAY-115 (Y59S and
K61L) and MAY-131 (K61N and G64E) escape mutants. These
changes were introduced into the MAYV-CH infectious cDNA
plasmid (Weise et al., 2014), and mutant viruses were produced.
As expected, these mutant viruses were neutralized by the anti-
E2MAY-117 (Fig. 4 H). In comparison, bothMAY-115 (Fig. 4 I) and
MAY-131 (Fig. 4 J) showed reduced neutralizing activity against
viruses containing any of the single mutations. All of the
neutralizing mAbs we mapped localized to sites proximal to the
FL in the E1 protein of the heterodimer (Fig. 4 K; E2 B domain
mAb epitopes in blue, E1 domain II mAb epitopes in magenta, and
FL in green).
Protection against lethal MAYV challenge by mAbs
To determine if mAbs could protect in vivo, we developed a
challenge model of MAYV infection in mice that resulted in
uniformmortality. 4-wk-old C57BL/6 mice were administered
a single intraperitoneal injection of 100 µg of anti-interferon
alpha and beta receptor subunit 1 (anti-Ifnar1) mAb (MAR-
5A3; Sheehan et al., 2006) 1 d before subcutaneous inoculation
with MAYV strain BeH407 in the footpad. Although MAYV is
not lethal in immunocompetent mice, infected animals treated
with anti-Ifnar1 mAbs began to succumb at 3 d post infection
(dpi) and experienced 100% mortality by 6 dpi (Fig. 5, A and
B). To test whether anti-MAYV mAbs could protect in this
model, we administered a single 100-µg mAb dose as pro-
phylaxis 1 d before virus inoculation. Even though many mAbs
had strong neutralizing activity (11 had EC50 values against
MAYV BeH407 of <10 ng/ml, and 17 had values <100 ng/ml),
only 9 of 18 protected mice against lethal challenge (Fig. 5, A
and B), with only two mAbs (MAY-115 and MAY-134) pre-
venting mortality completely. Remarkably, all of the mAbs
that protected mice against lethal MAYV infection were of the
IgG2a subclass (Fig. 5 B). Despite similar EC50 values to their
IgG2a counterparts (Table 1), strongly neutralizing anti-
MAYV IgG1 mAbs failed to protect against virus-induced
mortality (Fig. 5 A).
For the protective IgG2a mAbs, we determined their thera-
peutic activity in a postexposure treatment design. We admin-
isteredMAY-115,MAY-122,MAY-131,MAY-133,MAY-134,MAY-139,
or MAY-140 as well as the slightly protective (MAY-121) and non-
protective (MAY-117)mAbs 24 h after virus inoculation of anti-Ifnar1
mAb–treated mice. Only MAY-115 and MAY-134 conferred sub-
stantial protection, with 80% and 100% survival rates, respectively
(Fig. 5, C and D). Because MAY-115 and MAY-134 bound distinct
epitopes (Fig. 4 B), we tested them in combination. We treated mice
with 200 µg ofMAY-115, MAY-134, or a combination of 100 µg each
of MAY-115 and MAY-134 at 1, 2, or 3 dpi in the lethal challenge
model. The higher dose of antibody conferred protection in all mice
treated 1 dpi (Fig. 5 E). MAY-115 and MAY-134 protected 50% and
60% of mice when given individually at 2 dpi, whereas combination
therapy protected all mice (Fig. 5 F).When treatmentwas begun at 3
dpi, MAY-115 or MAY-134 protected 10% and 30%, respectively,
whereas combination therapy protected 50% of mice (Fig. 5 G).
Thus, a combination of anti-E1 and E2 mAbs provided superior
therapeutic activity compared with the individual mAbs against
MAYV in the lethal challenge model.
Protection against MAYV-induced musculoskeletal disease by
mAbs
As MAYV causes arthritis and musculoskeletal disease, we as-
sessed whether our protective mAbs also mitigated joint-
associated infection and swelling. 4-wk-old C57BL/6 mice were
inoculated subcutaneously in the foot with MAYV-BeH407, and
ipsilateral and contralateral ankle joint swelling was measured.
Table 2. Cross-reactivity of anti-MAYV mAbs with other alphaviruses
Antibody MAYV UNAV CHIKV RRV ONNV
MAY-115 + + − − −
MAY-116 + + + − −
MAY-117 + + + + −
MAY-118 + + + − −
MAY-119 + + + − −
MAY-120 + + + + −
MAY-121 + + + + −
MAY-122 + + − − −
MAY-125 + + + − −
MAY-130 + + + − +
MAY-131 + + − − −
MAY-133 + + − − −
MAY-134 + + − − −
MAY-139 + − − − −
MAY-140 + − − − −
MAY-146 + + + − −
MAY-147 + + − − −
MAY-151 + + + − −
Vero cells infected with the indicated alphavirus were incubated with anti-
MAYV mAbs. Binding to infected cells was determined by flow cytometry.
Data are representative of two experiments performed in triplicate. +
indicates cross-reactive and − indicates non–cross-reactive.
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Figure 3. Neutralizing mAbs block MAYV infection at postattachment steps. (A and B) Attachment inhibition assay. MAYV-CH was incubated with
soluble heparin (0.5 to 2 mg/ml; A), BSA (0.5–2 mg/ml; A), or anti-MAYV mAbs (10 µg/ml; B) for 1 h before addition to Vero cells at 4°C. After unbound virus
was removed by extensive rinsing, cell-adsorbed viral RNA was quantified by qRT-PCR, standardized to GAPDH levels, and plotted relative to an untreated
(A) or isotype mAb-treated (B) control. Data are the mean and SD of three experiments performed in triplicate (one-way ANOVA with Dunnett’s post-test
compared with the isotype control mAb). (C) Pre/postattachment neutralization assays. Serial dilutions of anti-MAYV mAbs were incubated with 102 FFU of
MAYV and added to Vero cells. Infection proceeded for 18 h before foci were stained, counted, and plotted relative to a no-antibody control. Data are the mean
and SD of two experiments performed in triplicate. (D) Postattachment neutralization assay. 102 FFU of MAYV was adsorbed to Vero cells at 4°C. Unbound
virus was removed by extensive washing, and serial dilutions of anti-MAYV mAbs were added. Infection proceeded for 18 h at 37°C. Viral foci were stained,
counted, and plotted relative to a no-mAb control. (E and F) FFWO assay. Cells were incubated with virus at 4°C. After removing unbound virus by rinsing, cells
were treated with 1 µg/ml of the indicated mAbs and then pulsed for 2 min with medium at pH 7.6 (E) or pH 5.5 (F) at 37°C. After pH neutralization, cells were
cultured in medium supplemented with 20 mM NH4Cl to prevent viral fusion via canonical endosomal pathways. Fusion inhibition was measured by flow
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In the ipsilateral ankle, MAYV caused swelling beginning at
2 dpi that persisted until ∼12 dpi (Fig. 6, A and B); in the con-
tralateral ankle, swelling was observed at 7 dpi (Fig. 6 A). We
tested mAbs with therapeutic activity in the lethal challenge
model for their ability to limit MAYV-associated joint swelling
along with the nonprotective MAY-117 (IgG1) and an isotype
control mAb. For each mAb, 100 µg was administered 1 d before
subcutaneous inoculation with MAYV-BeH407, and ankle
swelling was measured using digital calipers (Fig. 6, B–G).
Compared with an isotype control mAb, all tested anti-MAYV
mAbs reduced swelling in both the ipsilateral and contralateral
feet. MAY-115, MAY-130, MAY-131, and MAY-133 blocked
swelling in both feet. Mice treated withMAY-117, which failed to
protect against lethal challenge in anti-Ifnar1 mAb–treated mice,
showed swelling of the contralateral foot, although less than the
isotype control mAb (Fig. 6 C). Animals treated with MAY-122
exhibited a partial reduction in swelling of the ipsilateral foot
and delayed swelling in the contralateral foot (Fig. 6, D and E).
To determine the effect of anti-MAYV mAbs on viral dis-
semination, we treated mice in the musculoskeletal disease
model with either highly (MAY-115 or MAY-134) or partially
(MAY-117) protective mAbs. Mice treated with MAY-115 or
MAY-134 had less viral RNA in the ipsilateral foot at 1 dpi
compared with the isotype control, and viral RNA was cleared at
7 dpi (Fig. 6, H and I). Mice treated with MAY-117 had less viral
RNA in the ipsilateral foot than animals given the isotype control
mAb but had higher levels at both 1 and 7 dpi than animals
treated with MAY-115 or MAY-134. Consistent with these data,
MAY-115 and MAY-134 prevented viral dissemination to the
contralateral foot and the draining lymph node, whereas MAY-
117 did not (Fig. 6, J–M).
Antibody effector functions are required for anti-MAYV
mAb–mediated protection
We observed marked differences in mAb protection against
MAYV challenge (Fig. 5) despite similarities in neutralization
potency and epitope localization (Table 1 and Fig. 4). Because the
protective IgG2a mAbs against MAYV bound avidly to viral
antigens on the surface of infected cells (Table 3), we hypothe-
sized that optimal in vivo activity required Fc effector functions
of the antibody and recognition of viral proteins on the plasma
membrane. To begin to evaluate the contribution of Fc effector
functions to protection, we tested the ability of anti-MAYV
mAbs to promote neutrophil and monocyte-dependent phago-
cytosis of beads coated with recombinant MAYV E2 protein; we
were unable to express MAYV E1 protein and thus could not
interrogate anti-E1 mAbs for these studies. Several of the pro-
tective anti-MAYV E2 mAbs (e.g., MAY-122, MAY-133, and
MAY-134) promoted phagocytosis of MAYV antigen–coated
beads in murine neutrophils and monocytes (Fig. S5, A and B).
Capillary electrophoresis analysis revealed heterogeneity in the
abundance of specific glycans on anti-MAYV E2 mAbs (Fig. S5
C). Dominant afucosylated, digalactosylated, and sialylated
(G2S1 and GS2S) glycans appeared to associate positively with
protection, whereas fucosylated (G2S1F) and highly inflamma-
tory agalactosylated (G0) glycoforms were negatively associated
(see Table 3).
We next evaluated the effect of mAb isotype on protective
anti-MAYV mAb activity in anti-Ifnar1 mAb-treated C57BL/6
mice lacking the common signaling γ chain and activating FcγRs
(FcγR−/−). We performed prophylaxis studies with MAY-115 and
MAYV-134 by administering 100 µg of mAb 1 d before virus
inoculation. Isotype control mAb–treated FcγR−/−mice sustained
100%mortality by day 4 (Fig. 7 A), whereas animals treated with
MAY-115 or MAY-134 were protected only partially, with a
30–40% survival rate, respectively. This result contrasts with
the ability of the mAbs to confer complete protection as pro-
phylaxis in anti-Ifnar1 mAb–treated WT mice (see Fig. 5). As
expected,MAY-117, a neutralizingmAb of the IgG1 isotype, failed
to protect against MAYV in FcγR−/− mice.
To further define the role of mAb subclass in MAYV pro-
tection, we performed isotype-switching studies. Antibody iso-
types bind FcγRs with different affinities: mouse IgG2a binds
strongly to mouse FcγR I and FcγR IV, whereas mouse IgG1 does
not (Mancardi et al., 2008). We cloned the variable regions of
MAY-115 and MAY-134 and inserted them into mouse IgG1 and
IgG2a antibody heavy chain expression vectors. We also cloned
the variable regions of MAY-115 and MAY-134 as human IgG1
antibodies, which have comparable binding to mouse FcγR I and
FcγR IV as mIgG2a (Dekkers et al., 2017). Finally, we generated
an aglycosyl variant of human IgG1 (N297Q) that abrogates
binding to FcγR and C1q (Tao and Morrison, 1989). We first
tested the binding of the isotype-switched mAbs to mouse and
human FcγRs by ELISA; we observed little or no binding of
mouse IgG1 and human IgG1-N297Q antibodies to mouse FcγR I,
mouse FcγR III, mouse FcγR IV, human FcγR I, and human FcγR
IIIa (Fig. 7 B). Human IgG1 mAbs bound to mouse FcγR I and
FcγR IV similarly to mouse IgG2a but showed less binding to
mouse FcγR III. FRNT assays confirmed that isotype-switched
mAbs retained neutralizing activity (Fig. 7, C and D). As ex-
pected, all isotype-switched variants of MAY-115 had similar
defects in protection against MAYV challenge in FcγR−/− mice
(Fig. 7 E).
We administered the isotype-switched mAbs to mice in both
the lethal challenge and musculoskeletal disease models. When
switched frommouse IgG2a to IgG1, bothMAY-115 andMAY-134
lost their ability to fully protect mice, with 60% of animals
succumbing in each case (Fig. 7, F and H). Human IgG1 isotype-
switched variants of MAY-115 and MAYV-134 exhibited slightly
reduced activity in vivo compared with mouse IgG2a but were
cytometry by staining cells for MAYV E2 antigen 18 h later. Data are the mean and SD of three experiments performed in duplicate (one-way ANOVA with
Dunnett’s post-test compared with the isotype mAb control). (G and H) Egress inhibition assay. RNA isolated from MAYV-infected cells was transfected into
Vero cells. Medium was added with the indicated concentrations of anti-MAYV mAbs. RNase A–resistant encapsidated viral RNA in the supernatant was
quantified by qRT-PCR at 1 h (G) or 6 h (H) after transfection. Data are the mean and SD of three experiments performed in duplicate (one-way ANOVA with
Dunnett’s post-test compared with the isotype mAb control). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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Figure 4. Mapping of neutralizing anti-MAYV mAbs to sites within E1 and E2 proteins. (A–C) Solvent-exposed residues on the MAYV E2 B domain were
changed to the indicated amino acids. WT and mutant MAYV B domain proteins were purified, and binding to anti-MAYV mAbs was tested by ELISA. Regions
were divided into groups A (blue), B (red), and C (green) based on patterns of mutations that resulted in loss of binding of mAbs. Representative mAbs from
each group are shown (MAY-117, group A [A]; MAY-125, group B [B]; and MAY-139, group C [C]), with the remainder of the data in Fig. S4. (D–F) 293T cells
were transfected with a C-E3-E2-6K-E1 plasmid containing alanine mutations in the B domain of E2 and tested for binding with anti-MAYV mAbs by flow
cytometry. Additional arginine or glutamic acid changes were made to residues in two loops in the B domain (residues 179–186 and 212–218). Representative
mAbs from three binding groups are shown (MAY-117, group A [D]; MAY-125, group B [E]; and MAY-139, group C [F]), with the remainder of the data in Fig. S4.
Critical residues were defined as those with ≤25% binding to an individual mAb but ≥75% binding to an oligoclonal pool of anti-MAYVmAbs. Data are from three
experiments performed in triplicate. Error bars represent SD within one experiment. (G) Alignment of the B domain of E2 of MAYV, UNAV, CHIKV, RRV, and
ONNV with the critical interaction residues identified for each mAb marked. Residues mapped by structure-guided mutagenesis and ELISA (circles), alanine
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more protective than mouse IgG1 or human IgG1-N297Q mAbs.
Combination therapy experiments showed decreased efficacy
when one of the two mAbs was a human IgG1-N297Q variant,
suggesting that protection depends on effector functions of both
mAbs (Fig. S5 D). In the musculoskeletal disease model, all
isotype-switched mAbs reduced joint swelling in the ipsilateral
foot compared with isotype control mAbs, although differences
were apparent (Fig. 7, G and I). Whereas mouse IgG2a and hu-
man IgG1 forms of MAY-115 and MAY-134 mAbs prevented
swelling completely, mouse IgG1 and human IgG1-N297Q var-
iants showed only partial decreases in swelling. We observed
roughly equivalent half-lives of all of the isotype-switched mAbs
we tested (Fig. S5, E–J), which indicated that the decreased
protection observedwith particular mAb variants was not due to
more rapid clearance in vivo.
Even though many of our IgG1 mAbs had similarly potent
neutralizing activity against MAYV compared with IgG2a mAbs,
they failed to protect against lethal challenge. To corroborate
a key role for IgG subclass in protection against MAYV, we
switched the isotype of MAY-117 and MAY-130, two non-
protective neutralizing mAbs, from mouse IgG1 to human
IgG1, which engage FcγRsweakly and strongly, respectively. The
isotype-switched mAbs had similar neutralization activity
against MAYV BeH407 as the parental mAbs (Fig. 7, J and K). As
expected, uniform mortality was seen in MAYV-infected mice
treated with the mouse IgG1 forms of MAY-117 or MAY-130
(Fig. 7 L). In contrast, we observed significant protection against
lethal MAYV challenge when mAbs MAY-117 or MAY-130 of the
human IgG1 isotype was administered. These experiments
confirm that effector functions contribute to optimal antibody-
mediated protection of mice from lethal MAYV infection.
Discussion
Our goal was to produce type-specific and broadly neutralizing
mAbs that have therapeutic utility and can shed light on the
requisite components of a protective humoral immune response
against MAYV. We generated 151 hybridomas and identified 18
that produced mAbs with potent neutralizing activity. Of these,
11 had “elite” activity, with EC50 values against the immunizing
MAYV strain of <10 ng/ml. 16 of these mAbs neutralized the
closely related UNAV, with a smaller subset showing a breadth
of inhibitory activity against the more distant CHIKV, RRV,
and ONNV.
AlthoughmanymAbs neutralized a broad spectrum ofMAYV
isolates from both the D and L genotypes, there were exceptions.
MAY-133 had no neutralizing activity against MAYV-Uruma,
and MAY-140 lacked activity against MAYV-FSB0311, MAYV-
OBS6443, and MAYV-BeH473130. This observation was unex-
pected, because both mAbs engage residues (for MAY-133: Q183,
Q184, I190, G209, T210, I217, N218, and D223; for MAY-140:
Q183, I190, G209, T210, I217, and D223) on the E2 protein that are
shared by other mAbs that neutralized all MAYV strains and
even some other alphaviruses. Indeed, these interaction residues
are conserved across all MAYV strains that we tested. Although
further studies are warranted, we hypothesize that the display
of particular residues on E2 varies in a strain-dependent man-
ner, which could affect neutralization by a given antibody. Thus,
substitutions in the envelope proteins of Uruma, FSB0311,
OBS6443, and BeH473130 strains of MAYV could affect epitope
exposure, as has been described for flaviviruses (Austin et al.,
2012; Goo et al., 2017; Fernandez et al., 2018). Analysis of the
virion structures of these different MAYV strains and the dis-
play of their structural glycoproteins may elucidate why certain
antibodies fail to neutralize individual viruses even though their
binding residues appear conserved.
The neutralizing mAbs that we characterized all blocked
virus entry at postattachment steps. Only mAbs MAY-117 and
MAY-122 showed nominal blocking of viral binding to cells,
and these mAbs also blocked postattachment entry steps. The
majority of the mAbs, with the exception of MAY-120 and
MAY-122, inhibited plasma membrane fusion. These results
are similar to studies with other alphaviruses, including
CHIKV (Fox et al., 2015; Jin et al., 2015, 2018), Venezuelan
equine encephalitis (Porta et al., 2014), and eastern equine
encephalitis virus (Kim et al., 2019), indicating that potently
neutralizing mAbs may share a common mechanism of action.
Indeed, all of the strongly inhibitory mAbs we analyzed bound
to regions in E2 and E1 that are proximal to the FL peptide.
While entry blockade likely contributed to the potency of
virus neutralization, 16 of the 18 mAbs also inhibited viral
egress. This activity may occur as a result of cross-linking of
adjacent E protein complexes at the cell surface and/or con-
formational shifts induced by anti-B domain antibodies (Jin
et al., 2015, 2018) that prevent budding from infected cells. As
the regions in E1 and in the B domain of E2 to which our mAbs
mapped are conserved among MAYV strains, they could be
targeted by vaccines to induce broadly inhibitory humoral
responses against MAYV and closely related viruses.
Although all of the neutralizing E2-specific anti-MAYVmAbs
that we mapped localized to the B domain, it is likely that that
neutralizing epitopes also exist in the A domain. Neutralizing
mAbs that bind to the A domain of E2 of CHIKV (Fox et al., 2015;
Jin et al., 2015, 2018; Smith et al., 2015) and eastern equine
scanning mutagenesis and flow cytometry (triangles), or both (squares) are marked. Boxes around amino acids 179–186 and 212–218 indicate loops in the B
domain. Bars above the B domain indicate regions used to define binding groups A (blue), B (red), and C (green). (H–J) Neutralization escape mutants were
generated by serial passage of MAYV (strain CH) in the presence of MAY-115 or MAY-131. Sequence-confirmed mutations were introduced into an infectious
cDNA clone of the parental MAYV strain and tested for neutralization by MAY-117 (H), MAY-115 (I), or MAY-131 (J). Data are representative of two experiments
performed in triplicate. Error bars represent SD within on experiment. (K) Key residues necessary for mAb engagement are highlighted on the surface
representation of CHIKV (Basore et al., 2019; left; PDB: 6NK5) and depicted as balls and sticks on a ribbon diagram of the predicted structure of MAYV E2-E1
monomer generated using Phyre2 (right). Inset: Zoomed-in view of a trimeric spike. The E1 glycoprotein is in light gray, with the FL in green and the B-, C-, and
D-strands of domain II in cyan. The E2 glycoprotein is in dark gray, with the B domain in yellow. Epitope-mapped residues in E2 domain B and E1 domain II are
colored in blue and magenta, respectively.
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encephalitis virus (Kim et al., 2019) have been described. Fur-
thermore, vaccine-generated anti-MAYV-neutralizing anti-
bodies preferentially bound to epitopes within the A domain of
E2 (Choi et al., 2019). Our isolation of B rather than A domain
mAbs may be a product of our vaccination strategy. Although
the initial immunization and the final boosts were performed
with infectious virus, we boosted with recombinant E2 protein,
which may have skewed the immune response toward B domain
antibodies. Analysis of the antibody responses of different
mouse strains or naturally infected humans will be necessary to
establish the immunodominance of neutralizing epitopes in the
MAYV envelope proteins.
The neutralizing mAbs showed disparate levels of protection
in mice. Although many had exceptional neutralizing potency in
cell culture, only 8 of the 18 mAbs conferred significant pro-
tection in vivo. In this subset, there were differing levels of
Figure 5. Antibody protection against lethal MAYV challenge. A lethal MAYV challenge model was developed by treating 4 wk-old C57BL/6J male mice
with a single 100-µg dose of anti-Ifnar1 mAb 1 d before subcutaneous virus inoculation. (A and B) Prophylaxis studies. A single dose of anti-MAYV mAbs (100
µg/mouse; ∼6/mg/kg) was administered 1 d before inoculation with MAYV-BeH407, and survival was monitored. Antibodies are presented in IgG subclass
groups: mouse IgG1 (A) or mouse IgG2a (B). Data are from two experiments. (C and D) Therapeutic studies. Indicated mAbs (100 µg/mouse) were given 1 d
after virus inoculation, and survival was monitored. Data are from two experiments. (E–G) Combination mAb therapy. 200 total µg of MAY-115, MAY-134, or a
combination (100 µg each) was given to mice beginning at 1, 2, or 3 dpi, and survival was monitored. Data are from two experiments. In this figure, n = 10, log-
rank test with Bonferroni correction compared with the isotype mAb control treated group. *, P < 0.05; ***, P < 0.001.
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protection ranging from partial to complete protection (Table 3),
and there was no correlationwith the shape of the neutralization
curve or presence of a resistant fraction. The most protective
anti-E2mAbs bound viral antigen on the surface of infected cells
with high avidity and promoted phagocytosis of E2 protein–
coated beads by both neutrophils and monocytes. These results
are consistent with prior studies with the related Sindbis and
Semliki Forest viruses, which showed that nonneutralizing
mAbs can protect against lethal infection (Schmaljohn et al.,
1982; Wust et al., 1987). We observed a preliminary correlation
with protection in vivo and dominant afucosylated, digalacto-
sylated, and sialylated glycan specifies (sialic acid: G2S2 and
G2S1). The cytotoxic function of afucosylated glycans, which
enhance Fc-effector function, coupled to enhanced gal-
actosylation/sialylation, which dampen inflammation (Kaneko
et al., 2006; Anthony et al., 2008), may promote optimal viral
clearance and minimize pathology. Further glycan analysis and
protection data with a larger panel of anti-MAYV mAbs is
needed to corroborate these results, as was performed with
anti-Ebola virus mAbs (Saphire et al., 2018).
Figure 6. Antibody protection of MAYV-induced musculoskeletal disease. (A) Swelling observed in the ipsilateral (4 dpi, left) and contralateral (7 dpi,
right) ankle following infection withMAYV-BeH407. (B–G) Protective mAbs in the lethal challengemodel (Fig. 5) were tested for activity against MAYV-induced
musculoskeletal disease. 4-wk-old C57BL/6J male mice were given 100 µg of indicated mAbs via intraperitoneal route 1 d before subcutaneous inoculation of
103 FFU MAYV-BeH407 in the foot. Swelling was measured in the ipsilateral (B, D, and F) and contralateral (C, E, and G) ankles using digital calipers. Data are
the mean and SEM of two experiments (n = 10 mice, two-way ANOVA with Tukey’s post-test). (H–M) Virus titers in the ipsilateral (H and I) or contralateral
(J and K) feet or draining inguinal lymph node (L and M) at 1 (H, J, and L) and 7 (I, K, and M) dpi after prophylaxis of mice with 100 µg of the indicated mAbs.
Animals were perfused with PBS before tissue collection. Viral titers were determined by qRT-PCR. Data are from two experiments (n = 10 mice, one-way
ANOVA with Dunnett’s post-test). *, P < 0.05; **, P < 0.01; ***, P < 0.001, ****, P < 0.0001. The experiments in B, D, and F or C, E, and G were performed
concurrently, and thus a single isotype control mAbs was used and included in each graph.
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Antibody protection against lethal challenge and muscu-
loskeletal disease required Fc effector functions, albeit the
latter to a lesser degree. Our 18 neutralizing mAbs were
composed of two IgG subclasses: 10 IgG1 and 8 IgG2a. Re-
markably, only the IgG2a anti-MAYV mAbs conferred sub-
stantial protection against lethal challenge. Mouse IgG2a
antibodies not only interact with more FcγRs on immune cells
but also bind specific receptors (e.g., FcγR I) with higher af-
finity than IgG1 (Mancardi et al., 2008; Dekkers et al., 2017).
The capacity for an IgG subclass to engage FcγRs correlated
with in vivo activity, as MAY-115 and MAY-134 were more
protective as IgG2a than IgG1 antibodies even though their
neutralizing activity in vitro and half-lives in vivo were es-
sentially equivalent. The dependence of protection on effector
function was corroborated by comparing isotype-switched
anti-MAYV human IgG1 variants with and without (N297Q)
heavy-chain N-linked glycosylation. Moreover, nonprotective
mouse IgG1 mAbs (MAY-117 and MAY-130) became protective
when they were switched to a human IgG1 subclass, which
engages activating FcγRs more efficiently. The contribution of
FcγRs to anti-MAYV-mediated protection was confirmed
through challenge studies in mice lacking all activating FcγRs.
Antibody recognition of MAYV or other alphavirus antigens
on the cell surface may be an important mechanism for
clearance of infected cells through Fc effector–function de-
pendent phagocytosis or cytolysis by specific myeloid cell
subsets (Fox et al., 2019). Studies are planned to define the
dominant effector functions and individual FcγRs that con-
tribute to mAb protection in our MAYV models, as has been
performed to varying degrees with antibodies against influ-
enza (DiLillo et al., 2014), hepatitis B (Li et al., 2017), human
immunodeficiency virus (Hessell et al., 2007), West Nile virus
(Vogt et al., 2011), and CHIKV (Fox et al., 2019). Experiments
are needed to determine if other IgG subclasses (e.g., mouse
IgG2b, human IgG2, and human IgG3) confer protection
against MAYV in these models and whether there is an impact
of C1q, which differentially binds IgG subclasses, on protec-
tion. Finally, our combination therapy studies with MAY-115
and MAY-134, which bind discrete epitopes on E1 and E2
proteins, suggest that inclusion of multiple mAbs in a cocktail
likely will confer greater protection than either constituent
alone. This effect could be due to synergy of neutralization,
effector functions, or the control of resistance against either
of the two individual mAbs (Pal et al., 2013, 2014).
Antibodies with similar neutralization profiles and mecha-
nisms of action did not protect mice from MAYV infection
equivalently. Thus, the importance of IgG subclass and effector
function activity likely should be optimized for vaccines or
therapeutic antibodies against MAYV and other alphavirus in-
fections. Three candidate MAYV vaccines have been described,
including a chemically inactivated virion (Robinson et al., 1976),
a live-attenuated virus (Weise et al., 2014), and a DNA plasmid
vaccine (Choi et al., 2019). Although all protected in mice, the
antibody repertoires were not fully analyzed. Whereas the DNA
plasmid vaccine produced IgG2a antibodies inmice, the majority
were against epitopes on E1 and E2 not identified in our screens.
Our results in mice suggest than immunization strategies that
use protein scaffolds (Correia et al., 2014) and specific TH1-
skewing adjuvants could target regions in the B domain of E2,
the FL of E1, and possibly other sites to generate neutralizing
antibodies that block viral fusion and egress and optimize Fc
effector functions.
Table 3. Summary of properties of anti-MAYV IgG2a mAbs
Antibody Binding group Protection (%) EC50 binding EC50 neutralization Glycans ADNP ADCP
MAY-134 E2: A, C 100 31 (24–47) 9 (4–13) G2S2, G2S1, G2S1F, ++ ++
G0F, G1F, G2F
MAY-122 E2: B 80 7 (5–11) 3 (2–6) G2S2, G2S1F, G0F, ++ +
G1F-G1FB, G2F
MAY-133 E2: A, C 70 27 (21–38) 25 (14–44) G2S2, G2S1, G0F, ++ ++
G1F-G1FB, G2F
MAY-139 E2: C 70 18 (9–55) 246 (133–342) G2S2, G2S1, G2S1F, G0, − −
G0F, G1F-G1FB, GIFB-G2, G2F
MAY-125 E2: B 60 3 (2–8) 22 (14–42) G0F, G1F-G1FB, − −
G1FB-G2, G2F
MAY-140 E2: A 0 16 (12–22) 18 (11–30) G0F, G1F − −
MAY-115 E1 100 2 (1–7) 2 (1–3) N/A N/A N/A
MAY-131 E1 50 2 (1–4) 8 (2–14) N/A N/A N/A
IgG2a mAbs that bind to MAYV-E2 (top) or E1 (bottom) are listed along with the mapped binding group, percentage of mice protected from lethal challenge,
EC50 values for binding to MAYV-BeH407 infected Vero cells (EC50 binding) at 4°C, neutralization of MAYV-BeH407 (EC50 neutralization), glycan profile, and
antibody-dependent neutrophil phagocytosis and antibody-dependent cellular phagocytosis activity. Antibodies are listed in order from most protective to
least protective in each class. EC50 values are nanograms per milliliter. ADCP, antibody-dependent cellular phagocytosis; ADNP, antibody-dependent
neutrophil phagocytosis; N/A, not applicable.
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Materials and methods
Animal ethics statement
All animal experiments and procedures were performed in ac-
cordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health, Bethesda, MD. The protocols were approved by the In-
stitutional Animal Care and Use Committee at the Washington
University School of Medicine (assurance number A3381-01).
Injections were performed under anesthesia that was induced
and maintained with ketamine hydrochloride and xylazine, and
all efforts were made to minimize animal suffering.
Cell lines
Vero, HEK-293T, C2C12, and MEF cells were cultured in DMEM
supplemented with 10% FBS, 100 U/ml penicillin, 100 µg/ml
streptomycin, 1× MEM nonessential amino acids, 1 mM sodium
pyruvate, 2 mM L-glutamine, and 10 mM Hepes, pH 7.3. Hy-
bridomas were cultured in IMDM supplemented with 20% FBS,
100 U/ml penicillin, 100 µg/ml streptomycin, and 1 mM sodium
pyruvate. Expi293 cells were maintained in Expi293 medium
(Gibco).
Viruses
MAYV strains (Beh428890, BeH473130, BeH343155, BeH506151,
FSB0311, IQU2950, OBS6443, TRVL15537, BeH407, and Uruma),
CHIKV (La Reunion OPY1), UNAV (CoAr2380), RRV (T48), and
ONNV (M30) all were obtained from the World Reference
Center for Emerging Viruses and Arboviruses (R. Tesh, K.
Plante, and S. Weaver, University of Texas Medical Branch,
Galveston, TX) and passaged in Vero cells from lyophilized
stocks. Recombinant viruses were produced after linearization
of a prS2 vector containing cDNA from MAYV strain CH (Weise
et al., 2014) that was generously provided by S. Weaver (Uni-
versity of Texas Medical Branch, Galveston, TX). After in vitro
transcription with mMESSAGE mMACHINE SP6 transcription
kit (Invitrogen) and transfection into BHK-21 cells, p0 virus
stocks were harvested and passaged once (p1) in Vero cells. Vi-
rus titers were determined by focus forming assay (Fox et al.,
2015).
Mouse studies
4-wk-old WT C57BL/6J male mice were purchased from the
Jackson Laboratory. 4-wk-old common γ-chain–deficient
(FcRγ−/−) C57BL/6 mice were obtained commercially (Ta-
conic) and bred at the Washington University Animal Facility.
Anti-MAYV mAbs were administered by intraperitoneal in-
jection at specified times before or after inoculation in the left
footpad with 103 focus-forming units (FFU) MAYV in HBSS
supplemented with 1% heat-inactivated FBS. Foot swelling was
monitored via measurements (width × height) using digital
calipers. Tissues were harvested after perfusion with 40ml PBS
and titered by qRT-PCR using RNA isolated from viral stocks as
a standard curve to determine FFU equivalents. For lethal
challenge experiments, mice were administered via intraperi-
toneal injection a single 100-µg dose of anti-Ifnar1 mAb MAR1-
5A3 (Sheehan et al., 2006; Bio X Cell) 1 d before infection.
mAb generation
10-wk-old female BALB/c mice were inoculated with 103 FFU of
MAYV-CH. Mice were boosted with 100 µg of recombinant
MAYV E2 protein mixed 1:1 with Freund’s incomplete adjuvant
at 14, 28, and 42 d after initial infection. At 56 dpi, mice were
boosted with 106 FFU of MAYV-CH. 3 d before splenocyte har-
vest, at 70 dpi, mice were inoculated with 1010 FFU of MAYV-CH
that was produced by centrifugingMAYV through a 20% sucrose
cushion at ∼175,000 ×g for 2 h. Spleens were harvested at 73 dpi
and fused with P3X63 Ag.8.6.5.3 mouse myeloma cells as de-
scribed previously (Pal et al., 2013). Hybridoma supernatants
were screened for antibodies that bound to recombinant MAYV
E2 in an ELISA and/or to MAYV-infected cells by flow cytome-
try. Neat hybridoma supernatants were screened for neutrali-
zation of MAYV-CH using an FRNT (described below). Selected
mAbs were isotyped by ELISA and purified by protein A affinity
columns using a commercial vendor (Bio X Cell).
FRNTs
Anti-MAYV mAbs were diluted serially and incubated with 102
FFU of the specified MAYV strain for 1 h at 37°C in triplicate
wells. Virus-mAb mixtures were incubated on Vero cells for
60 min at 37°C before being overlaid with 1% methylcellulose in
MEM supplemented with 10 mM Hepes, pH 7.3, 100 U/ml of
penicillin, 100 µg/ml of streptomycin, 2 mM L-glutamine, and
2% FBS. 18 h after virus inoculation, cells were fixed with 1%
paraformaldehyde (PFA) in PBS. Cells were then washed and
incubated with 1 µg/ml CHK-48 (Fox et al., 2015), a cross-
reactive anti-CHIKV mAb, for 2 h. Cells were washed and
Figure 7. Antibody protection against MAYV depends on the IgG subclass and Fc effector functions. (A) 4-wk-old C57BL/6 male and female FcγR−/−
mice were administered 100 µg of the indicated anti-MAYV mAbs and 100 µg of anti-Ifnar1 mAb 1 d before subcutaneous inoculation with 103 FFU of MAYV-
BeH407. Data are from two experiments. (B) Recombinant, isotype-switched mAbs (MAY-115 and MAY-134) were tested by ELISA for binding to soluble mouse
and human FcγRs. Binding is presented relative to the mouse IgG2a isotype control of MAY-115 (left) or MAY-134 (right). Data are the mean and SD of two
experiments performed in triplicate. (C and D) Neutralizing activity of isotype-switched MAY-115 (C) or MAY-134 (D) was measured by FRNT against MAYV-
BeH407. Data are representative of three experiments performed in triplicate. (E) 4-wk-old FcγR−/− mice were administered 100 µg of the indicated MAY-115
IgG and 100 µg of anti-Ifnar1 mAb 1 d before subcutaneous inoculation with 103 FFU of MAYV-BeH407. Data are from two experiments. (F–I) Protection by
isotype-switched mouse IgG2a mAbs. MAY-115 (F and G) and MAY-134 (H and I) isotype-switched mAbs were tested as prophylaxis against lethal challenge
(F and H) or musculoskeletal disease (G and I) as described in Figs. 5 and 6. Survival data are from two experiments. Swelling data are the mean and SD from
two experiments (n = 10 mice, two-way ANOVA with Sidak’s post-test). (J–L) Protection by isotype-switched mouse IgG1 mAbs. MAY-117 (J) and MAY-130 (K)
isotype-switched mAbs were tested as prophylaxis against lethal challenge (L). Survival data are from two experiments (A, E, F, H, and L; n = 10 mice, log-rank
test with Bonferroni correction compared with the isotype control or indicated treatment groups). The experiments in F and H or G and I were performed
concurrently, and thus a single isotype control mAbs was used and included in each graph. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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incubated with 500 ng/ml HRP-conjugated goat anti-mouse IgG
(Sigma-Aldrich) for 1 h. Foci of infection were detected using
TrueBlue substrate (KPL) and counted using a Biospot plate
reader (Cellular Technology). Wells containing virus incubated
with mAbs were compared with wells treated with virus con-
taining no mAb. The EC50 value was calculated using nonlinear
regression analysis after constraining the bottom to 0 and the
top to 100.
Attachment inhibition assay
104 FFU of MAYV was incubated with mAbs, soluble heparin
(H3393; Sigma), or BSA (Sigma) at the specified concentration
for 1 h at 37°C. The mixture was chilled on ice and added to Vero
cells and incubated at 4°C for 1 h. Cells were washed six times
with chilled PBS before addition of lysis buffer and extraction of
RNA using an RNAeasy Mini Kit (QIAGEN). MAYV RNA was
quantified using a Taqman RNA-to-Ct 1-step kit (Thermo Fisher
Scientific) and a 59 untranslated region and nsp1 specific primer/
probe set (Waggoner et al., 2018). MAYV RNA levels were
normalized to GAPDH, and the relative fold change was com-
pared with cells treated with an isotype control mAb.
Pre- and postattachment assays
Pre- and postattachment neutralization assays were performed by
first incubating serially diluted anti-MAYV mAbs with 102 FFU of
MAYV for 1 h at 37°C. The mAb–virus complexes were then added
to Vero cells for 1 h at 37°C. Cells were overlaid with 1% (wt/vol)
methylcellulose in modified Eagle medium supplemented with 2%
FBS. Postattachment neutralization assays were performed by first
incubating Vero cells with 102 FFU of MAYV for 1 h at 4°C. Cells
were washed extensively with cold DMEM to remove unbound
virus. Diluted anti-MAYVmAbswere added to virus-adsorbed cells
and incubated for 1 h at 4°C. After a 15-min incubation at 37°C to
allow virus internalization, cells were overlaid with methylcellu-
lose. Pre- and postattachment neutralization assays were processed
similarly using the FRNT described above.
Fusion inhibition assays
FFWO assays were performed after allowing virus adsorption to
BHK-21 cells (multiplicity of infection [MOI] of 25) for 1 h at 4°C.
Unbound virus was removed by rinsing cells with chilled PBS.
Diluted anti-MAYV mAbs (1 µg/ml) were added to virus-
adsorbed cells for 30 min at 4°C. Cells were washed with chil-
led PBS. FFWO was induced by pulsing with fusion medium
(RPMI 1640, 10 mM Hepes, 0.2% BSA, and 30 mM succinic acid,
pH 5.5) for 2 min at 37°C. A nonfusion control was included
using control media (RPMI 1640, 10mMHepes, pH 7.6, and 0.2%
BSA). After the pulse, cells were washed twice with chilled PBS
and incubated in DMEM supplemented with 5% FBS, 10 mM
Hepes, pH 7.3, 100 U/ml of penicillin, 100 µg/ml of streptomy-
cin, and 20 mM NH4Cl to prevent de novo infection via canon-
ical endocytosis pathways. Infection was allowed to proceed for
6 h, and cells were detached and fixed with 4% PFA in PBS. Cells
were stained with MAY-118 (0.5 µg/ml) in permeabilization
buffer (PBS + 1% BSA + 0.1% saponin) and incubated for 1 h at
4°C. After two washes with permeabilization buffer, MAYV E2
antigen was detected with Alexa Fluor 647–conjugated goat
anti-mouse IgG (1:1,000 dilution; Thermo Fisher Scientific).
After two washes with permeabilization buffer, cells were
resuspended in 100 µl and analyzed on a MACSQuant Ana-
lyzer (Miltenyi Biotec).
Egress inhibition assays
Vero cells were inoculated withMAYV at anMOI of 0.1. After 24
h, cells were washed and lysed, and total RNA was collected
using an RNAeasy Mini kit (QIAGEN). The amount of viral RNA
present was measured by qRT-PCR, and the stocks were ali-
quoted and stored at −80°C. Vero cells were transfected with
viral RNA (equivalent to an MOI of 10) and incubated for 3 h at
37°C. The cell culture media was replaced with 50 µl of medium
containing dilutions of anti-MAYV mAbs. The cells then were
incubated for 3 h at 37°C before supernatant was collected. The
samples were incubated with PBS containing 50 µg/ml RNase A
(Sigma) to remove nonencapsidated RNA. RNA was isolated
from the supernatant using an RNAeasy Mini kit, and MAYV
RNA was measured using qRT-PCR as described above.
Protein expression and purification
The MAYV E2 ectodomain (residues 1–340) was cloned into the
pET21a expression vector and expressed in BL21 (DE3) Esche-
richia coli cells. Protein production was induced using 1 mM
IPTG, where E2 partitioned into the inclusion body fraction and
was refolded using an oxidative refolding protocol (Nelson et al.,
2014). Briefly, 10 ml solubilized inclusion body was injected at
1 ml/h into a 1-liter volume of arginine refolding buffer (400mM
L-arginine, 100 mM Tris, pH 8.5, 5 mM reduced glutathione,
0.5 mM oxidized glutathione, and 0.2 mM PMSF) and then al-
lowed to stir slowly overnight at 4°C. The refolded protein was
filtered, concentrated using a 30-kD-cutoff stirred cell concen-
trator (EMD Millipore), and purified by HiLoad 16/600 Super-
dex 75 size exclusion chromatography (GE Healthcare). B
domain mutants were generated using a QuikChange II XL Site-
Directed Mutagenesis Kit (Agilent) and verified by DNA se-
quencing. Mutants were confirmed by direct sequencing of
plasmid DNA and expressed and purified as described above.
MAYV E2-E1 structure prediction and substitution design
The predicted structure of the MAYV E2-E1 heterodimer
was generated for strain TRVL4675 (GenBank accession no.
AAO33335.1) using the intensive modeling mode of Phyre2
(Kelley et al., 2015). Cutoffs of residues to display were based on
the crystal structure of CHIKV p62E1 (PDB: 3N42; Voss et al.,
2010). Substitution mutations in the B domain of E2 were de-
signed by first estimating the solvent accessibility of each resi-
due using Naccess (Hubbard and Thornton, 1993). A residue was
chosen to undergo substitution if it was predicted to be solvent
accessible and conserved among arthritogenic alphaviruses, but
not encephalitic alphaviruses.
BLI binding assays
The binding affinity of purified recombinant MAYV E2 ectodo-
main protein to MAYV mAbs was monitored at 25°C using an
Octet-Red96 device (Pall ForteBio). 100 µg of each mAb was
mixed with biotin (EZ-Link-NHS-PEG4-Biotin; Thermo Fisher
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Scientific) at a molar ratio of 20:1 biotin/protein and incubated
at room temperature for 30 min. The unreacted biotin was re-
moved by passage through a desalting column (5 ml Zeba Spin
7 kD molecular weight cutoff; Thermo Fisher Scientific). The
biotinylated mAbs were loaded onto streptavidin biosensor pins
(ForteBio) until saturation, typically 10 µg/ml for 2 min, in
10 mM Hepes, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% P20
surfactant, and 1% BSA. The pins were equilibrated in binding
buffer alone before being plunged into wells containing various
concentrations of MAYV E2 and then placed back into binding
buffer to allow for dissociation. Real-time data were analyzed
using BIAevaluation 3.1 (GE Healthcare). Kinetic profiles and
steady-state equilibrium concentration curves were fitted using
a global 1:1 binding algorithm with drifting baseline.
MAYV mAb mapping by ELISA
Purified recombinant MAYV E2 ectodomain WT or mutant
proteins (100 ng/well) were adsorbed overnight at 4°C on
Maxisorp immunocapture ELISA plates (Thermo Fisher Scien-
tific) in a sodium bicarbonate buffer (pH 9.3). Plates were
washed three times with PBS and 0.05% Tween 20 for 1 h at 37°C
followed by incubation of 0.5 µg/ml of indicated mAbs for 1 h at
room temperature. Plates were washed again and then se-
quentially incubated with 2 µg/ml of HRP-conjugated goat anti-
mouse IgG and tetramethylbenzidine substrate (Invitrogen). The
reaction was stopped by the addition of 1 N H2SO4, and emission
at 450 nmwas read using an iMark microplate reader (Bio-Rad).
Critical residues were defined as those with ≤25% binding to an
individual mAb but ≥75% binding to an oligoclonal pool of anti-
MAYV mAbs.
Alanine scanning mutagenesis
A pcDNA3.1(+) plasmid expressing a codon-optimized MAYV-
TRVL4675 structural polyprotein (C, E3, E2, 6K, and E1 genes)
was synthesized and mutated by Genewiz. Alanine scanning
mutagenesis was performed on amino acids in the B domain of
the E2 protein (residues 189–231), whereas charge mutations to
arginine were made on residues 179–186 and 212–218, with the
exception of 215, which was changed to glutamic acid. Plasmids
were transfected into HEK-293T cells using Lipofectamine 3000
(Thermo Fisher Scientific). 18 h later, cells were chilled to 4°C,
washed with PBS, and incubated with anti-MAYVmAbs (10 µg/ml)
in PBS with 2% FBS for 1 h at 4°C. An oligoclonal mixture of all
the anti-MAYV mAbs was used as a control for mutant E2
protein expression. Anti-MAYV mAb binding was detected
using Alexa Fluor 647–conjugated goat anti-mouse IgG (Thermo
Fisher Scientific) diluted 1:1,000. After 1 h, cells were washed,
fixed with 1% PFA in PBS and analyzed by flow cytometry using
a MACSQuant Analyzer (Miltenyi Biotec). Using previously
described criteria (Smith et al., 2015), critical residues were
defined as thosewith ≤25% binding to an individualmAb but ≥75%
binding to an oligoclonal pool of anti-MAYV mAbs when detected
by flow cytometry.
Generation of neutralization escape mutants
105 FFU of MAYV-CH was incubated with 1 µg/ml of MAY-115 or
MAY-131 for 1 h at 37°C. The virus–mAb mixtures were added to
Vero cells. After 24 h, half of the virus supernatant was frozen at
−80°C, whereas the other half was incubated with 1 µg/ml of
MAY-115 or MAY-131 for 1 h at 37°C. This virus–mAb mixture
was added to Vero cells and harvested after 24 h. This protocol
was performed a total of six passages before escape mutants
were confirmed by FRNT. Viral RNA was isolated from super-
natant pools using a MagMAX Viral Isolation kit (Applied
Biosystems), and cDNA was generated using SuperScript IV
Reverse transcription using Oligo(dT)20 primers (Thermo Fisher
Scientific). Viral structural genes were amplified using the for-
ward primer 59-GGTCCTAAATAGGTGCTCTACACG-39 and re-
verse primer 59-ACTTTGAGAAGGTRAATCAWAAGTACCG-39.
The amplicons were sequenced by Genewiz, and mutants were
produced using a Phusion Site-Directed Mutagenesis Kit
(Thermo Fisher Scientific) in the MAYV-CH infectious cDNA
clone described above.
Isotype switching of mAbs
MAY-115 and MAY-134 variable regions were sequenced and
cloned using previously described methods (Ho et al., 2016).
Total RNA was isolated from hybridomas, and cDNA was pro-
duced using random hexamers and Oligo(dT)20 using a Super-
Script IV First Strand Synthesis kit (Invitrogen). Heavy and light
chain variable regions were amplified and sequenced using
mouse-specific primer sets (Ho et al., 2016). Allele-specific pri-
mers were used to amplify variable regions and append Gibson
assembly sequences to the 59 and 39 ends. The variable regions
then were cloned into plasmids containing the constant regions
of human IgG1 (pAbVec-hIgG1) or mouse IgG1 (pAbVec-mIgG1)
or the appropriate kappa chain (pAbVec-hIgKappa or pAbVect-
mIgKappa) using NEBuilder (New England Biolabs). The human
IgG1-N297Q vector was produced by site-directed mutagenesis
of the human IgG1 vector using a Phusion site-directed muta-
genesis kit. Antibodies were produced by cotransfecting Expi293
cells with an appropriate heavy and kappa chain plasmid using
Hype5 transfection reagent (Oz Biosciences). 4 d after trans-
fection, supernatant was collected and mAbs were purified on a
Protein A Agarose column (Pierce).
Antibody half-life measurement
4-wk-old WT C57BL/6J male mice were administered 200 µg of
anti-MAYV mAbs by intraperitoneal injection. At specified time
points, mice were euthanized and perfused with 40 ml PBS, and
feet were collected. The supernatant from foot homogenates was
analyzed for anti-MAYV mAbs by whole-virus capture ELISA
using a standard curve of MAY-115 mIgG2a. Briefly, ELISA plates
were coated with 104 FFU/well MAYV-CH at 4°C overnight.
Plates were blocked using 5% BSA in PBS for 2 h at 37°C and then
incubated for 2 h with serial dilutions of foot homogenate su-
pernatant in parallel with a serial dilution of a known quantity
of MAY-115 mIgG2a. After washing, bound antibody was de-
tected using goat anti-mouse or anti-human HRP-conjugated
antibodies (1:1,000; Southern Biotech). Plates were developed
using tetramethylbenzidine substrate (Invitrogen), and the re-
action was stopped with H2SO4. ELISA plates were read using a
TriBar LB941 plate reader (Berthold Technologies). The optical
density values from the known quantity of MAY-115-mIgG2a
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were fitted to a standard curve and compared with the optical
density values of the foot homogenate supernatant to determine
amount of MAYV-specific antibody present in the tissue.
FcγR ELISA
ELISA plates were coated with 200 ng/well of soluble FcγR
proteins (R&D Systems) at 4°C overnight. Plates were blocked
using 5% BSA in PBS for 2 h at 37°C. Anti-MAYV mAbs were
added (1 µg/well) and incubated at room temperature for 2 h.
Unbound antibody was washed from the plate, and bound an-
tibody was detected as described above.
Next-generation sequencing
Following vRNA extraction of MAYV strains, samples were
amplified using a random RT-PCR protocol. The resulting am-
pliconswere used to generate a library using the NEBNext (NEB)
kit with indexing as described (Zhao et al., 2017). Libraries from
multiple indexed samples were pooled and sequenced on the 2 ×
250 bp Illumina MiSeq platform. Consensus sequences were
generated using Geneious v10.2.2 by mapping short reads onto
the genome of MAYV-BeH742930.
Antibody binding to infected cells
Vero cells were inoculated with MAYV-BeH407 at an MOI of 1.
18 h later, cells were detached with TrypleE (Thermo Fisher
Scientific) and washed with PBS supplemented with 2% BSA at
4°C. Cells were incubated with fivefold dilutions (1 µg/ml to 20.5
pg/ml) of anti-MAYVmAbs for 30min at 4°C. BoundmAbs were
detected using an Alexa Fluor 647–conjugated goat anti-mouse
IgG antibody (Thermo Fisher Scientific) before fixation with 2%
PFA for 10 min. Antibody-bound cells were detected by flow
cytometry using a MACSQuant analyzer (Miltenyi Biotec). The
percentage of cells positive for a given mAb was compared with
cells stained with a saturating amount of (100 µg/ml) an oligo-
clonal mixture of anti-MAYV mAbs. Binding EC50 values were
determined by plotting the percentage of positive cells relative
to the oligoclonal mAb control and fitting the data to a nonlinear
regression curve.
Antibody-dependent neutrophil phagocytosis
Recombinant MAYV E2 protein was biotinylated and conjugated
to streptavidin-coated Alexa Fluor 488 beads. MAYV E2–coated
beads were incubated with fivefold dilutions of antibodies (mAbs:
5–0.0016 µg/ml) in cell culture medium for 2 h at 37°C. Bone
marrow cells were harvested from C57BL/6 mice. Cells were
washed with PBS, and 5.0 × 104 cells per well were added to bead-
antibody immune complexes and incubated for 1 h at 37°C. Cells
were stained with the following antibodies: CD11b APC (cloneM1/
70; BioLegend), CD11c APC/Cy7 (clone N418; BioLegend), Ly6G
Pacific Blue (clone 1A8; BioLegend), Ly-6C BV605 (clone HK1.4;
BioLegend), and CD3 PE/Cy7 (clone 17A2; BioLegend). Cells were
fixed with 4% PFA and analyzed on an IntelliCyt iQue Screener
Plus flow cytometer. Neutrophils were defined as CD3− and
CD11c− cells that were Ly6C−, CD11b+, and Ly6G+. The phagocytic
score was determined using the following calculation: (percent-
age of Alexa Fluor 488+ cells) × (Alexa Fluor 488 geometric mean
fluorescent intensity of Alexa Fluor 488+ cells)/10,000.
Antibody-dependent cellular phagocytosis
Recombinant MAYV E2 protein was biotinylated and conjugated
to streptavidin-coated Alexa Fluor 488 beads. MAYV E2–coated
beads were incubated with fivefold dilutions of antibodies
(mAbs: 5–0.0016 µg/ml) in cell culture medium for 2 h at 37°C.
J774A.1 (TIB-67; ATCC) murine monocyte cells were added to
bead–antibody immune complexes (5.0 × 104 cells per well) and
incubated for 1 h at 37°C. Cells were washed in 5 mM EDTA PBS,
fixed with 4% PFA, and analyzed on an IntelliCyt iQue Screener
Plus flow cytometer. The phagocytic score was determined using
the following calculation: (percentage of Alexa Fluor 488+ cells) ×
(Alexa Fluor 488 geometric mean fluorescent intensity of Alexa
Fluor 488+cells)/10,000.
Glycan analysis
The relative abundance of antibody glycan structures was
quantified by capillary electrophoresis, as previously described
(Mahan et al., 2015). Briefly, mAbs were purified using protein G
magnetic beads (New England Biolabs) and then treated with
IdeZ protease (New England Biolabs) to release the antibody Fab
portion. The Fc-attached beads were washed, and N-glycans
were removed from the Fc domains and labeled with 8-amino-
pyrene-1,3,6-trisulfonic acid (APTS) using the GlycanAssure
APTS Kit (Thermo Fisher Scientific), as described in the man-
ufacturer’s protocol. Labeled glycans were loaded onto the 3500
Genetic Analyzer (Thermo Fisher Scientific). Peaks for differ-
entially galactosylated, fucosylated, bisected (GlcNAc), and sia-
lylated structures were identified (13 peaks were reproducibly
observed). The relative abundance of each glycan structure was
determined by calculating the area under the curve, normalized
for equal amounts of loaded APTS dye, of each peak divided by
the total area of all peaks.
Statistical analysis
Statistical significance was assigned with P values <0.05 using
GraphPad Prism version 7.0. The specific test for each dataset is
indicated in respective figure legends and was selected based on
the number of comparison groups and variance of the data. For
foot swelling analysis, significance was determined by a two-
way ANOVA with Tukey’s post-test (more than two groups) or
Sidak’s post-test (between two groups). Viral burden data were
analyzed by a one-way ANOVA with a Dunnett’s post-test.
Survival curve analysis was analyzed by the log rank test. A
Bonferroni correction was used depending on the number of
comparison groups.
Data availability
Next-generation sequencing data have been deposited in the
National Center for Biotechnology Information Trace and Short-
Read Archive accession number PRJNA525867 and consensus
sequences were deposited with GenBank accession numbers
MK573238–MK573246. No proprietary software was used in the
data analysis.
Online supplemental material
Fig. S1 shows the neutralization curves for eachmAbwith each h
strain of MAYV. Figs. S2 and S3 show an amino acid alignment
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and relative identity of MAYV E1 and E2 proteins, respectively,
of the strains used in this study. Fig. S4 shows binding data of
the mAbs to E2 and E2 B domain in ELISA as well as the full
dataset of antibody mapping data for each mAb. Fig. S5 shows
the glycan profile and antibody effector activity for the anti-
MAYV E2 mAbs as well as the half-lives of the isotype
switched mAbs in vivo. Table S1 provides strain information for
the strains used in this study. Table S2 provides kinetic and
equilibrium binding values for the mAbs for MAYV E2 protein
measured by BLI.
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Figure S1. Anti-MAYV mAbs neutralization of different MAYV strains. Related to Fig. 1. Serial dilutions of mAbs were incubated with 102 FFU of the
indicated MAYV strain before inoculation of Vero cells, unless otherwise indicated. mAb neutralization of MAYV-BeH407 also was tested in C2C12 myoblasts
and MEFs. Cells were overlaid with methylcellulose and incubated for 18 h. Viral foci were stained, counted, and plotted relative to a no-antibody control. Data
are representative of two experiments performed in triplicate. Error bars represent SD within one experiment.
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Figure S2. Amino acid alignment of MAYV E1 proteins. Related to Figs. 1 and 4 and Table 1. (A) MAYV strains were subjected to next-generation se-
quencing, and the consensus E1 amino acid sequences were compiled and aligned using Geneious v10.2.2 software. Red indicates sequence agreement among
strains, whereas residues that vary among strains are highlighted white. Components of domains I (DI), II (DII), and III (DIII), the FL (orange), and the stem,
transmembrane, and cytoplasmic tail (black) are indicated above the sequences. Predicted β-sheet (arrows) and α-helical (spirals) secondary structure are
indicated above the sequences. (B) The amino acid similarity was compiled in a matrix with each strain. TM, transmembrane.
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Figure S3. Amino acid alignment ofMAYV E2 proteins. Related to Figs. 1 and 4 and Table 1. (A)MAYV strains were subjected to next-generation sequencing
and consensus E2 amino acid sequences were compiled and aligned using Geneious v10.2.2 software. Sequence agreement among strains is indicated by red
color whereas residues that vary among strains are highlighted in white. Components of domains A, B, C, the B-linker, and the stem, transmembrane, and
cytoplasmic tail (dark blue) are indicated above the sequences. Predicted β-sheet (arrows) and α-helical (spirals) secondary structure are indicated above the
sequences. (B) The amino acid similarity was compiled in a matrix with each strain. TM, transmembrane.
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Figure S4. Binding and mapping of mAbs to recombinant MAYV E2-B domain. Related to Fig. 4. (A and B) Binding of mAbs to E2 protein. ELISA plates
were coated with 100 ng/well of recombinant MAYV E2 (A) or the E2 B domain (B) before incubation with 500 ng/ml of anti-MAYV mAbs. Antibody binding to
recombinant proteins was detected by an anti-mouse secondary antibody. Binding of the mAbs to the proteins is shown relative to an oligoclonal mixture of
MAYV mAbs. Data are the mean and SD of two experiments, each with three replicates. (C and D) Mapping of anti-E2 mAbs to MAYV B domain. E2 B
domain–specific mAbs were mapped by ELISA (C) and flow cytometry (D) as described in Fig. 4.
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Figure S5. Effector function and glycan profiles of anti-MAYV mAbs. Related to Fig. 7. (A and B) Anti-MAYV E2 mAbs were evaluated for neutrophil- (A)
and monocyte-dependent (B) phagocytosis of MAYV E2 protein-conjugated beads relative to a no-antibody–treated control; data are the average of two
experiments performed in duplicate. Error bars represent SD of each replicate. (C) The glycan profiles of the mAbs were detected by capillary electrophoresis
of isolated Fc regions. The relative abundance of the indicated glycans is shown with glycans present shaded in blue. (D) Efficacy of combination therapy with
isotype switched mAbs. 100 µg each of a combination of MAY-115 and MAY-134 of the indicated IgG subclass was given to anti-Ifnar1 mAn treated mice
beginning at 2 dpi, and survival was monitored. Data are from two experiments (n = 10). (E–J) The clearance rate of isotype-switched mAbs in vivo. Antibody
clearance in vivo. WT C57BL/6J mice were inoculated with 200 µg/mouse of MAY-115 (E–G) or MAY-134 (H–J) of mouse IgG2a (E and H), human IgG1 (F and I),
or human IgG1-N297Q (G and J). At the indicated time points, mice were sacrificed and perfused with PBS. The feet were harvested, homogenized, and analyzed
for levels of anti-MAYV mAbs by ELISA.
Table S1. MAYV strains
Strain GenBank accession number Genotype Date isolated Source of isolate Country of origin
CH DQ487410 D 1997 Human Peru
BeH343155 MK573244 D 1978 Human Brazil
BeH506151 MK573241 D 1991 Human Brazil
FSB0311 MK573245 D 2002 Human Bolivia
IQU2950 MK573243 D 2000 Human Peru
Uruma MK573246 D 1955 Human Bolivia
TRVL15537 MK573240 D 1957 Mosquito Trinidad
OBS2209 MK573242 D 1995 Human Peru
BeH407 MK573238 L 1955 Human Brazil
BeH473130 KY618133 L 1988 Human Brazil
BeH428890 MK573239 L 1984 Human Brazil
MAYV strains used in this study are listed along with GenBank accession numbers, genotype, isolation date, host source, and country of origin. All strains were
provided by the World Reference Center for Emerging Viruses and Arboviruses and described in Powers et al. (2006).
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Table S2. Kinetic and equilibrium binding to E2 protein by anti-MAYV mAbs as measured by BLI
MAYV mAb ka (105 M−1 s−1) kd (10−4 s−1) t1/2 (s) KD, kinetic (nM) KD, equilibrium (nM)
115 n.b. n.b. n.b. n.b. n.b.
116 1.72 ± 0.29 17.7 ± 4.1 405 ± 90 10.8 ± 4.5 19.9 ± 2.1
117 2.84 ± 0.72 8.49 ± 1.58 834 ± 141 3.25 ± 1.56 10.6 ± 2.5
118 3.07 ± 0.67 22.8 ± 3.6 309 ± 48 7.91 ± 3.37 13.4 ± 4.0
119 2.45 ± 0.73 16.8 ± 2.0 417 ± 47 7.36 ± 2.98 14.3 ± 4.0
120 1.99 ± 0.23 16.0 ± 1.3 436 ± 35 8.05 ± 0.44 17.7 ± 1.0
121 1.38 ± 0.25 49.9 ± 7.0 141 ± 20 37.1 ± 8.9 46.6 ± 12.7
122 5.85 ± 0.20 8.52 ± 1.72 839 ± 191 1.45 ± 0.25 3.96 ± 0.78
125 1.01 ± 0.22 46.2 ± 2.7 150 ± 9 47.5 ± 12.1 58.3 ± 18.8
130 13.8 ± 2.4 10.3 ± 0.3 710 ± 187 0.78 ± 0.32 2.63 ± 0.93
131 n.b. n.b. n.b. n.b. n.b.
133 0.20 ± 0.02 49.7 ± 3.1 140 ± 9.0 257 ± 42 243 ± 64
134 0.28 ± 0.04 21.5 ± 7.4 346 ± 104 81.0 ± 37.3 151.5 ± 69.4
139 1.37 ± 0.20 11.4 ± 5.7 695 ± 269 8.90 ± 5.9 22.1 ± 11.0
140 0.23 ± 0.04 17.7 ± 1.3 393 ± 28 76.8 ± 7.1 170.2 ± 29.4
146 2.45 ± 0.42 20.0 ± 0.3 347 ± 5 8.33 ± 1.34 17.8 ± 4.9
147 0.73 ± 0.04 12.4 ± 1.8 567 ± 81 17.2 ± 3.5 38.0 ± 8.3
151 1.81 ± 0.29 38.1 ± 7.1 186 ± 35 21.6 ± 6.2 28.8 ± 7.1
Binding of anti-MAYV mAbs to recombinant MAYV E2 protein was measured by BLI. Values are mean ± SD of three experiments. The rates of association (ka),
disassociation (kd), the t1/2 of association, and the kinetic (KD, kinetic) and equilibrium (KD, equilibrium) association constants are shown with SDs. KD, kinetic = kd/ka;
t1/2 = ln(2)/kd. n.b., nonbinding; these mAbs recognize epitopes in E1 protein.
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